<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1314</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕРОПРИЯТИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EVENTS</subject></subj-group></article-categories><title-group><article-title>Разработку лекарственных средств, возрастозависимые заболевания и перспективы отечественной науки обсудят на OpenBio-2022</article-title><trans-title-group xml:lang="en"><trans-title>The development of medicines, age-related diseases and the prospects for domestic science will be discussed at OpenBio-2022</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редакционная</surname><given-names>статья</given-names></name><name name-style="western" xml:lang="en"><surname>Editorial</surname><given-names>Article</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2022</year></pub-date><volume>11</volume><issue>3</issue><fpage>44</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Редакционная с., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Редакционная с.</copyright-holder><copyright-holder xml:lang="en">Editorial a.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1314">https://www.pharmjournal.ru/jour/article/view/1314</self-uri><abstract><p>С 27 по 30 сентября в наукограде Кольцово Новосибирской области в девятый раз пройдет площадка открытых коммуникаций в сфере вирусологии, биотехнологий и биофармацевтики OpenBio. В программе OpenBio – трехдневная конференция молодых ученых, выставка достижений биотехнологических компаний и научно-деловой форум с дискуссиями по вопросам долголетия, разработке лекарств и реагентов, борьбе с возрастозависимыми заболеваниями, противодействия распространению ВИЧ-инфекции, импортозамещения и перспективам инвестирования в наукоемкий бизнес в современных реалиях.</p></abstract><trans-abstract xml:lang="en"><p>From September 27 to 30, the science city of Koltsovo, Novosibirsk Region, will host the OpenBio platform for open communications in the field of virology, biotechnology, and biopharmaceutics for the 9th time. The OpenBio program will include a three-day conference of young scientists, an exhibition of achievements of biotechnology companies and a scientific and business forum with discussions on longevity, the development of medicines and reagents, the fighting of age-related diseases, preventing the spread of HIV infection, import substitution and the prospects for investing in science-intensive business in modern realities.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
